Development of a CRISPR/Cas-Based Detection Platform for Tracking Decreased Susceptibility to Cephalosporins in Neisseria gonorrheae by Ziyuan Zhao (2889005)

“…Developing efficient and accurate detection of resistant strains is urgently needed for their management and treatment. We have developed the Multiplex Integrated RPA-CRISPR/Cas12a detection Assay (MIRCA) for simultaneous detection of Neisseria gonorrheae (<i>Ng</i>) and mutations with decreased susceptibility to cephalosporins. …”

Descriptive statistics (means) for full sample and by lockdown status. by Drew B. Cameron (10687420)

Subjects:

Study sites and number of participants enrolled in the KAP and OOP surveys. by Drew B. Cameron (10687420)

Subjects:

Average cost per visit for HIV and HTN care (absolute vs. relative contributions). by Drew B. Cameron (10687420)

Subjects:

GLM models for predictors of monthly HTN care costs. by Drew B. Cameron (10687420)

Subjects:

Median monthly care costs, projected visits, and hospitalization costs. by Drew B. Cameron (10687420)

Subjects:

List of captured wild pollinator species. by Carmelo Gómez-Martínez (9384385)

“…We found that orchards surrounded by a greater proportion of natural landcover received more visits by wild bees and butterflies and fewer by honeybees. …”

Map of the 20 study orchards. by Carmelo Gómez-Martínez (9384385)

“…We found that orchards surrounded by a greater proportion of natural landcover received more visits by wild bees and butterflies and fewer by honeybees. …”

Pictures of carob tree flowers and orchard. by Carmelo Gómez-Martínez (9384385)

“…We found that orchards surrounded by a greater proportion of natural landcover received more visits by wild bees and butterflies and fewer by honeybees. …”

Study Flowchart. by Jae-Heung Cho (798319)

Subjects:

Changes in outcomes over time. by Jae-Heung Cho (798319)

Subjects:

Study timetable. by Jae-Heung Cho (798319)

Subjects:

Cumulative incidence curves of recovery by group. by Jae-Heung Cho (798319)

Subjects:

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects: